{"denoms":[{"counts":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"54"}],"units":"Participants"}],"groups":[{"description":"Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Adenoid Cystic Carcinoma"},{"description":"Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"Non Adenoid Cystic Carcinoma"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"30","upperLimit":"82","value":"56"},{"groupId":"BG001","lowerLimit":"20","upperLimit":"71","value":"56"},{"groupId":"BG002","lowerLimit":"20","upperLimit":"82","value":"56"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"26"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"28"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}